Key facts
- It has raised $17.0M; the latest was Early Stage VC in Aug 2025.
- Notable investors include Fujian Huaxing Venture Capital, Beijing Zhenxin Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Hangzhou Adcoris Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Hangzhou Adcoris Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hangzhou Adcoris Biopharma
Developer of next-generation antibody bioconjugate therapeutics, focused on advancing ADC and AXC platforms for oncology and autoimmune diseases. The company specailises in proprietary cytotoxic payloads, cleavable and stable linkers, first-in-class and first-in-generation ADCs and AXCs, IND-enabling services and preclinical development, thereby accelerating drug discovery timelines and addressing unmet medical needs with targeted, high-efficacy therapies.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Employees
- 50
- Website
- adcoris.com.cn/
- Ownership
- Privately Held (backing)
Hangzhou Adcoris Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hangzhou Adcoris Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hangzhou Adcoris Biopharma in its N-PORT filings yet. We sweep new filings monthly.